Loading...
•
Dec 31, 2024
•/
Genmab Q4 2024 Earnings Report
Genmab reported strong financial performance in Q4 2024, driven by increased royalties and product sales.
Key Takeaways
Genmab delivered solid Q4 2024 results with revenue reaching DKK 21,526 million, an increase of 31% year-over-year. Net profit surged to DKK 7,844 million, supported by strong DARZALEX and Kesimpta royalties. Operating profit improved to DKK 6,703 million, while cash and cash equivalents stood at DKK 9,858 million.
Total revenue for Q4 2024 reached DKK 21,526 million, up 31% year-over-year.
Net profit for the quarter was DKK 7,844 million, significantly increasing from the prior year.
Operating profit came in at DKK 6,703 million, reflecting strong cost control and revenue growth.
DARZALEX and Kesimpta royalties were key revenue contributors, driving the increase.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Genmab expects continued revenue growth in 2025, driven by increasing royalties and product sales, with revenue projected between DKK 23.0–24.2 billion.
Positive Outlook
- DARZALEX and Kesimpta royalties expected to continue strong growth.
- EPKINLY and Tivdak product sales forecasted to expand in new markets.
- Increased investments in R&D expected to drive pipeline progress.
- Operational efficiency improvements to support profitability.
- Global market expansion plans to enhance revenue streams.
Challenges Ahead
- Higher operating expenses due to increased investment in late-stage programs.
- Potential regulatory challenges affecting product approvals in new markets.
- Competitive pressures from biosimilars and new entrants in oncology.
- Currency fluctuations could impact revenue and profitability.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...